ClinicalTrials.gg

Program

Microbial Collagenase

Also written as “EN3835”, “Santyl” and “AA4500”.

Its studies are mostly in Cellulite · Penile Induration · Dupuytren Contracture · Diabetic Foot · Bursitis, led by 5 companies.

Furthest: phase 4, since Dec 17, 201142 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keenova Therapeutics382 open or runningphase 4since Dec 17, 2011Sep 11, 2007Dec 2027phase 3 · NCT07759362
Advance Biofactures10 open or runningphase 1since Aug 22, 2016Aug 22, 2016none ahead
Asahi Kasei Therapeutics10 open or runningphase 3since Apr 27, 2012Apr 27, 2012none ahead
Luxurgery10 open or runningphase 4since Mar 24, 2022Mar 24, 2022none ahead
Manhattan Medical Research Practice, PLLC10 open or runningphase 4since Nov 30, 2018Nov 30, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 28 studies since Sep 11, 2007.

  1. Nov 30, 2018Manhattan Medical Research Practice, PLLC's first study: phase 4 study in Penile IndurationNew to Manhattan Medical Research Practice, PLLCManhattan Medical Research Practice, PLLC · NCT03767452 · 20 enrolled · United States
  2. Nov 18, 2019Phase 3 study in CelluliteKeenova Therapeutics · NCT04170296 · 153 enrolled · United States, Puerto Rico
  3. Dec 11, 2019Phase 2 study in CelluliteKeenova Therapeutics · NCT04209530 · 7 enrolled · United States
  4. Jan 2, 2020Phase 2 study in Characteristics of Subcutaneous TissueKeenova Therapeutics · NCT04236635 · 10 enrolled · United States
  5. Jul 29, 2020Phase 2 study in BursitisKeenova Therapeutics · NCT04496167 · 198 enrolled · United States
  6. Oct 2, 2020Phase 2 study in CelluliteKeenova Therapeutics · NCT04580303 · 35 enrolled · United States
  7. Nov 29, 2021Phase 2 study in Fibromatosis, PlantarKeenova Therapeutics · NCT05152173 · 176 enrolled · United States
  8. Feb 15, 2022Phase 3 study in Fibromatosis, PlantarKeenova Therapeutics · NCT05254457 · 145 enrolled · United States
  9. Mar 24, 2022Luxurgery's first study: phase 4 study in CelluliteNew to LuxurgeryLuxurgery · NCT05309525 · 17 enrolled · United States
  10. Jun 9, 2022Phase 2 study in CelluliteKeenova Therapeutics · NCT05419505 · 91 enrolled · United States
  11. Nov 21, 2023Phase 3 study in Fibromatosis, PlantarKeenova Therapeutics · NCT06151197 · 436 enrolled · United States, Puerto Rico
  12. Dec 5, 2023Phase 2 study in Fasciitis, PlantarKeenova Therapeutics · NCT06169319 · 231 enrolled · United States
  13. Aug 7, 2026Phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07759362 · 554 planned · United States
  14. Sep 23, 2026Phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07846280 · 470 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07759362
  2. Dec 2028Primary completion: phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07846280

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07846280Flexible Hammertoe · United States3RecruitingKeenova TherapeuticsDec 2028470
NCT07759362Flexible Hammertoe · United States3RecruitingKeenova TherapeuticsDec 2027554
NCT06169319Fasciitis, Plantar · United States2CompletedKeenova TherapeuticsSep 30, 2024231
NCT06151197Fibromatosis, Plantar · United States, Puerto Rico3CompletedKeenova TherapeuticsJun 9, 2026436
NCT05419505Cellulite · United States2CompletedKeenova TherapeuticsJan 3, 202391
NCT05309525Cellulite · United States4CompletedLuxurgerySep 1, 202217
NCT05254457Fibromatosis, Plantar · United States3CompletedKeenova TherapeuticsMar 21, 2024145
NCT05152173Fibromatosis, Plantar · United States2CompletedKeenova TherapeuticsJan 10, 2023176
NCT04580303Cellulite · United States2CompletedKeenova TherapeuticsAug 30, 202135
NCT04496167Bursitis · United States2CompletedKeenova TherapeuticsApr 14, 2022198
NCT04236635Characteristics of Subcutaneous Tissue · United States2CompletedKeenova TherapeuticsSep 23, 202010
NCT04209530Cellulite · United States2TerminatedKeenova TherapeuticsJul 23, 20207
NCT04170296Cellulite · United States, Puerto Rico3CompletedKeenova TherapeuticsOct 6, 2020153
NCT03767452Penile Induration · United States4UNKNOWNManhattan Medical Research Practice, PLLCDec 201920
NCT03675685Cellulite · United States1CompletedKeenova TherapeuticsNov 1, 201812
NCT03632993Cellulite · United States2CompletedKeenova TherapeuticsJan 24, 201964
NCT03526549Cellulite · United States3CompletedKeenova TherapeuticsOct 8, 2021483
NCT03446781Cellulite · United States3CompletedKeenova TherapeuticsSep 26, 2018422
NCT03428750Cellulite · United States3CompletedKeenova TherapeuticsSep 26, 2018423
NCT03329989Cellulite · United States2CompletedKeenova TherapeuticsSep 5, 2018158
NCT02942160Cellulite · United States2CompletedKeenova TherapeuticsJun 14, 2018259
NCT02889848Leiomyoma · United States1CompletedAdvance BiofacturesOct 5, 201815
NCT02724644Cellulite · United States2CompletedKeenova TherapeuticsSep 2016375
NCT02193828Dupuytren Contracture · United States, Australia2CompletedKeenova TherapeuticsDec 201476
NCT02006719Bursitis · United States, Australia2CompletedKeenova TherapeuticsDec 2014322
NCT01987986Cellulite · United States2CompletedKeenova TherapeuticsAug 2014150
NCT01685437Penile Induration3CompletedKeenova TherapeuticsDec 2013189
NCT01588353Dupuytren Contracture · Japan3CompletedAsahi Kasei TherapeuticsJan 2014104
NCT01518907Cellulite · United States1CompletedKeenova TherapeuticsDec 201299
NCT01498640Dupuytren Contracture · United States, Australia, Sweden and more4CompletedKeenova TherapeuticsOct 201352
NCT01483963Bursitis · United States2CompletedKeenova TherapeuticsFeb 201350
NCT01430169Penile Induration · United States2CompletedKeenova TherapeuticsNov 201120
NCT01407068Dupuytren Contracture · United States, Australia3CompletedKeenova TherapeuticsFeb 201260
NCT01243411Penile Induration · United States, Denmark, France and more3CompletedKeenova TherapeuticsAug 2012348
NCT01221623Penile Induration · United States, Australia3CompletedKeenova TherapeuticsMar 2012418
NCT01221597Penile Induration · United States, Australia3CompletedKeenova TherapeuticsApr 2012418
NCT00755222Penile Induration · United States2CompletedKeenova TherapeuticsDec 2009147
NCT00533273Advanced Dupuytren's Disease · Australia3CompletedKeenova TherapeuticsSep 200866
NCT00528931Dupuytren Contracture · United States1CompletedKeenova TherapeuticsDec 200716
NCT00528840Advanced Dupuytren's Disease · United States3CompletedKeenova TherapeuticsOct 2008201
NCT00528606Dupuytren Contracture · United States3CompletedKeenova TherapeuticsApr 2008308
NCT00528424Advanced Dupuytren's Disease · United States3CompletedKeenova TherapeuticsNov 2008286

How it is read

Names in the registry

  • “EN3835”, 9 entries
  • “Santyl”, 7 entries
  • “AA4500”, 7 entries
  • “collagenase clostridium histolyticum”, 5 entries
  • “Collagenase Clostridium Histolyticum”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.